Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00956228
First received: August 7, 2009
Last updated: February 23, 2011
Last verified: February 2011

August 7, 2009
February 23, 2011
October 2006
December 2007   (final data collection date for primary outcome measure)
  • The primary outcome will be assessment of toxicity as well as efficacy as determined by survival rates, freedom from biochemical relapse rates, local control rates, distant failure rates.
  • The main endpoint of the toxicity component is evaluating how many patients develop grade 3 or greater toxicity.
  • It is expected between 0 and 9% of patients will have grade 3 or 4 toxicity.
Same as current
Complete list of historical versions of study NCT00956228 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
Phase I/II Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer

The current study involves a novel and aggressive therapeutic approach for patients' prostate cancer. In addition, the investigators propose to administer hormonal therapy to patients with an especially high risk: those with initial Gleason scores of > 6, PSA > 10 ng/ml, T3/T4 primary tumors, and those found to be node positive (N+). The use of hormonal therapy in these specific settings correlates with our current standard of care. IMRT is better able to spare and protect normal tissues from receiving radiation than 3-D conformal RT. The radiotherapy would be followed by continued hormonal therapy for a total of 6 months in those who have one of the following Gleason 7 and PSA 10-20 and as per the previous version of this trial, 1 year similar to that delivered by the EORTC for higher risk patients, (those with initial Gleason scores of > 8, PSA > 20 ng/ml, or T3/T4 tumors). Those found to be N(+) would have the hormonal therapy continued indefinitely or until disease progression occurred in a manner analogous to the Messing et. al. series in prostatectomy patients. The goals are to develop and administer a program of treatment that includes the most recent developments in imaging, integrating data from both the CT scan and the ProstaScint scan to optimize prostate cancer RT. The CT scan will be used for staging and to determine the exact location of the entire prostate which will receive a reasonable dose of RT. The ProstaScint will be used to assess the spread of disease to lymph nodes as well as to determine the exact location of the tumor within the prostate gland. This region will then be boosted to a tumorcidal dose. The investigators then plan to monitor the toxicity and outcome of this treatment. The investigators expect that this program of radioimmunoguided IMRT will likely result in similar or less toxicity and increased cure rates when compared to conventional radiotherapy and standard IMRT programs.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Prostatic Neoplasm
Radiation: radioimmuniguided intenstiy modulated radiotherapy
All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
Experimental: Radioimmunoguided IMRT
All patients recieved Intensity Modulated Radiotherapy to the prostate with 75.6 Gy in 42 fractions. Additionally, they recieve a concurrent boost to the region of the prostate which enhanced on the prostascint scan to 82 Gy.
Intervention: Radiation: radioimmuniguided intenstiy modulated radiotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with pathologically proven prostate cancer
  • No evidence of distant metastases (M0) on physical examination, bone scan
  • ECOG PS 0,1,2
  • Adequate organ function as evidenced by:

    • Hemoglobin > 10.0 gm/dl
    • White blood count > 3000/mcL
    • Platelet count > 90,000/mcL
    • AST < 2x normal
  • Age > 18 years
  • Patients can not be allergic to Leuprolide or Goserelin if the pretreatment PSA > 20, Gleason Score > 8, T3/4, or N1 disease
  • Written informed consent
  • We anticipate enrolling at least 50 patients per year, which would bring accrual to projected total of 100 patients in 2 years

Exclusion Criteria:

  • None
Male
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00956228
390-02
Yes
Not Provided
Mayo Clinic
Not Provided
Not Provided
Mayo Clinic
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP